Mikio Sugimoto

发表

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

M. Oya, N. Mehra, C. Poehlein, 2023, The Lancet. Oncology.